EDAP Leverages Expertise in Distributing Innovative Urinary Systems

EDAP TMS S.A. Announces Exclusive Distribution of New Muscle Trainer Device in Japan Lyon, France, January 30, 2007 - EDAP TMS S.A. (Nasdaq: EDAP ), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development,

Company Now in Position to Roll-Out Its U.S. Strategy

Proceeds to Enhance Marketing to Accelerate Ablatherm-HIFU RPP Business in Europe

Clear Global Leader in Prostate Cancer HIFU Continues Market Acceleration Strengthening Its Position by Adding New RPP Sites

Mobile RPP Utilization Increasing, New Centers Added; Strong Commitment from Distribution Partne

Ablatherm-HIFU Tours to Accelerate HIFU Adoption for Prostate Cancer, Add New Users and Sites EDAP Marketing Programs Driving Patient Inquiries, Moving Doctors to Action

Europe's RPP Program: On Track to Group Profitability The USA: EDAP's New and Exciting Opportunity

HIFU Utilization Increasing as Company Accelerates Its Growth Program Company Adding Resources to Launch RPP Centers More Quickly

EDAP and HealthTronics in Discussions Realigning US Market Entry; Ablatherm RPP Success Growing Europe; Lithotripsy Returns to Profitability - Solid Cash Position for Continued Growth